EuBiologics Co Ltd
KOSDAQ:206650
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EuBiologics Co Ltd
Accumulated Depreciation
EuBiologics Co Ltd
Accumulated Depreciation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accumulated Depreciation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
E
|
EuBiologics Co Ltd
KOSDAQ:206650
|
Accumulated Depreciation
-₩60B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Accumulated Depreciation
-₩760.7B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-15%
|
|
|
O
|
OliX Pharmaceuticals Inc
KOSDAQ:226950
|
Accumulated Depreciation
-₩6.6B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Accumulated Depreciation
-₩12.5B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-34%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Accumulated Depreciation
-₩12B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Accumulated Depreciation
-₩7.6B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
EuBiologics Co Ltd
Glance View
EuBiologics Co., Ltd. engages in the research, development, and manufacture of biopharmaceutical products. The company is headquartered in Seoul, Seoul and currently employs 323 full-time employees. The company went IPO on 2017-01-24. The firm operates its business through two segments. The Vaccine segment manufactures and sells oral cholera vaccines. The Contract Research and Manufacturing Organization (CRMO) segment contracts, researches and manufactures biopharmaceuticals.
See Also
What is EuBiologics Co Ltd's Accumulated Depreciation?
Accumulated Depreciation
-60B
KRW
Based on the financial report for Dec 31, 2025, EuBiologics Co Ltd's Accumulated Depreciation amounts to -60B KRW.
What is EuBiologics Co Ltd's Accumulated Depreciation growth rate?
Accumulated Depreciation CAGR 5Y
-27%
Over the last year, the Accumulated Depreciation growth was -20%. The average annual Accumulated Depreciation growth rates for EuBiologics Co Ltd have been -22% over the past three years , -27% over the past five years .
